TG Therapeutics Inc (TGTX)

Debt-to-capital ratio

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Long-term debt	US$ in thousands	100,118	71,135	66,788	7,716	28,970
Total stockholders’ equity	US$ in thousands	160,502	58,587	237,153	519,350	38,615
Debt-to-capital ratio		0.38	0.55	0.22	0.01	0.43

December 31, 2023 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $100,118K ÷ ($100,118K + $160,502K)
= 0.38

The debt-to-capital ratio of TG Therapeutics Inc has fluctuated over the past five years. In 2023, the ratio stands at 0.38, indicating that 38% of the company's capital structure is financed through debt. This represents a decrease from 2022 when the ratio was 0.55. The significant decrease in the ratio from 0.55 in 2022 to 0.38 in 2023 suggests that the company may have reduced its reliance on debt financing in the most recent year.

Comparing the current ratio to the values in the preceding years, it is notable that the ratio was relatively low in 2020 at 0.01, indicating a minimal proportion of debt in the capital structure. However, there was a notable spike in the ratio in 2019 to 0.43, signifying a higher level of debt relative to capital.

Overall, the trend in the debt-to-capital ratio of TG Therapeutics Inc indicates variability in the company's debt management strategies over the years. The recent decrease in the ratio could imply a shift towards a more balanced capital structure or a deleveraging effort. Further analysis and consideration of the company's overall financial health and industry norms would provide a more complete understanding of its debt management practices.